Morphic Holding Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Morphic Holding Inc (MORF) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Morphic Holding Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 75M vs 481,101M combined for tracked competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $2.43M compares with $1.22M for the peer group (2.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Morphic Holding Inc vs. its Competitors, Q2 2024
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Morphic Holding Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Morphic Holding inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Morphic Holding Inc's competitor groups requires a Commercial License.
Morphic Holding Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Morphic Holding inc | - | - | - | No |
| Competitors combined (93) | ||||
| High-Confidence Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MORF Stock Performance relative to its Competitors
MORF Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 4 | Centessa Pharmaceuticals Plc | 282.9% | Outperformed |
| 5 | Prelude Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Morphic Holding Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Morphic Holding Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Morphic Holding inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Morphic Holding inc | 2,854.94 | 75.30 |
| Eli Lilly And Company | 1,062,533.34 | 79,665.80 |
| Beone Medicines Ltd | 545,678.64 | 6,128.24 |
| Abbvie Inc | 467,632.55 | 64,386.00 |
| Amgen Inc | 226,706.56 | 38,095.00 |
| Gilead Sciences Inc | 185,927.94 | 30,457.00 |
| SUBTOTAL | 3,474,472.95 | 511,049.07 |
Sign in to see all competitors of Morphic Holding inc .
Sources: Morphic Holding inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Morphic Holding inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Morphic Holding Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Named by the company | 85% |
| AbbVie | Named by the company | 85% |
| Biogen | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Roche Holding AG | Named by the company | 85% |
| Merck & Co., Inc. | Named by the company | 85% |
| UCB | Named by the company | 85% |
| Janssen | Named by the company | 85% |
| Scholar Rock | Named by the company | 85% |
| Eli Lilly And Company | Named by the company | 85% |
| Gilead Sciences Inc | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Morphic Holding Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Morphic Holding Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Morphic Holding inc | 2,855 | 2,429,000 | -5,800,839 |
| Eli Lilly And Company | 1,062,533 | 1,593,316 | 534,224 |
| Beone Medicines Ltd | 545,679 | 510,686 | 54,642 |
| Abbvie Inc | 467,633 | 1,129,579 | 110,807 |
| Amgen Inc | 226,707 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 185,928 | 1,791,588 | -190,588 |
| PEERS TOTAL | 3,471,618 | 1,216,642 | 156,466 |
Sign in to see all peers for Morphic Holding inc .
Morphic Holding Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Beone Medicines Ltd | United States 51.69 % |
| Gilead Sciences Inc | United States 70.78 % |
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Morphic Holding inc .
Morphic Holding Inc's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Morphic Holding inc .
Morphic Holding Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 2.8x | 4.5x | -1.7x |
| Return on Equity | -26.62 % | industry aggregate | -38.94 % |
| Return on Invested Capital | -15.75 % | -2.95 % (avg) | -12.80 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Morphic Holding Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | - | 257.72 % | - |
| Operating Margin | -484.02 % | -89.53 % | - |
| Return on Invested Capital | -12.09 % | -8.66 % | -13.86 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Morphic Holding Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 38.9 points below the industry aggregate.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-26.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Morphic Holding Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Morphic Holding inc | 2.58 | 31.38 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
Sign in to see all peers for Morphic Holding inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Morphic Holding Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Morphic Holding inc | Q2 2024 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| PEERS TOTAL | +9.9 % | -26.9 % |
Sign in to see all peers for Morphic Holding inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Morphic Holding Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Morphic Holding inc | Q2 2024 | - | -6.1 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
Sign in to see all peers for Morphic Holding inc .
Morphic Holding Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Morphic Holding inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
Sign in to see all peers for Morphic Holding inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Morphic Holding Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Morphic Holding inc | - | 37.91 |
| Eli Lilly And Company | 39.91 | 13.34 |
| Beone Medicines Ltd | 823.84 | 89.04 |
| Abbvie Inc | 74.59 | 7.26 |
| Amgen Inc | 25.88 | 5.95 |
| Gilead Sciences Inc | - | 6.10 |
| PEERS AVERAGE | 53.02 | 6.80 |
Sign in to see all peers for Morphic Holding inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.